Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action date for FDA decisionGepotidacin could be the first in a new class of oral ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...
GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.
GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...